--- title: "Oncology Center of Excellence - Avance Clinical" description: "To translate a novel cancer therapy into meaningful human data, you need specialist oncology leadership from first engagement with regulators through Proof of Concept." canonical: "https://www.avancecro.com/oncology-center-of-excellence/" generated: "2026-09-21T11:55:03+00:00" --- # Oncology Center of Excellence Smarter [Early Phase](https://www.avancecro.com/cro/phase-i-early-phase/) Oncology, Delivered [Early Phase](https://www.avancecro.com/cro/phase-i-early-phase/) oncology trials demand nuanced ethics, complex study designs, and disciplined patient selection – requirements that many generalist CROs aren’t built to support. To translate a novel cancer therapy into meaningful human data, you need specialist oncology leadership from first engagement with regulators through Proof of Concept. Avance Clinical’s Oncology Center of Excellence (COE) is purpose-built to help biotech sponsors move from first-in-human through Phase II with confidence – combining indication-level expertise, advanced trial design capabilities, and a global site network to keep timelines, budgets, and data quality on track. Learn more [Request A Proposal](https://www.avancecro.com/request-a-proposal/) ![](https://www.avancecro.com/wp-content/uploads/2026/06/Oncology-COE-3-aspect-ratio-1600-975-916x916.jpg) ## GET IN TOUCH WITH OUR **CLINICAL TRIAL EXPERTS** Three decades of experience in biotech drug development [Connect with us](https://www.avancecro.com/request-a-proposal/) ## Why Sponsors Choose a **Dedicated Oncology COE?** [Request A Proposal](https://www.avancecro.com/request-a-proposal/) ### Integrated design support, including adaptive and Bayesian dose-escalation strategies, to optimize dose finding and patient selection in complex solid and haematologic malignancies ### Oncology-focused site relationships across the U.S., U.K., EU, and APAC to unlock faster recruitment and access to diverse, often underutilized patient populations ### Specialized scientific and regulatory teams experienced with early phase oncology submissions, complex inclusion/exclusion criteria, and evolving global regulatory environments ### Senior oncology project leadership and operations to minimize study start up and activation delays, and data quality issues that erode timelines and budgets ### Continuity of team and strategy from dose-escalation through expansion and Phase II, enabling efficient data-driven program decisions and smoother geographic scale-up ## **Avance Clinical + LumaBridge** LumaBridge, Avance Clinical’s specialized, U.S.-based arm, is the Oncology Center of Excellence’s foundation, offering: - An expansive U.S. footprint - Deep medical, scientific, and clinical expertise - Strong site and investigator relationships Navigating complex clinical and regulatory pathways can be challenging. With our guidance biotech companies can: - Anticipate regulatory requirements and smoothly navigate FDA procedures - Pursue the most suitable target population and therapeutic area - Identify motivated investigators and key opinion leaders - Quickly adapt to changes in oncology standard of care - Reach critical milestones efficiently This combination of Avance Clinical and LumaBridge also makes it even easier for you to access the [Phase I](https://www.avancecro.com/cro/phase-i-early-phase/) market in [Australia](https://www.avancecro.com/the-australian-advantage/) and New Zealand and then quickly move your oncology innovation into global Phase II and III studies. ![](https://www.avancecro.com/wp-content/uploads/2026/02/iStock-1388388109-2048x1152-1-aspect-ratio-1600-975-916x916.jpg) ## **Start Smart, Scale With Confidence** With over 260 oncology trials delivered in the last five years, indication-specific experience, and repeat collaborations, Avance Clinical and LumaBridge provide focused [Early Phase](https://www.avancecro.com/cro/phase-i-early-phase/) execution across a broad range of solid and haematologic malignancies — shortening learning curves and enhancing feasibility and protocol design. **​Solid Tumors** - Glioblastoma multiforme (GBM) - Non‑small cell lung cancer - Hepatocellular carcinoma (HCC) - Melanoma - Head and neck cancers - Solid tumors including renal, breast, colorectal, ovarian, prostate, and all‑comer basket designs **Molecularly Defined/High‑Complexity Programs** - p53‑mutated tumors - Multi-indication solid tumor programs and novel modalities across RNAi, cell-based therapies, and targeted small molecules (where applicable to your portfolio) **Haematologic Malignancies** - Acute lymphoblastic leukemia (ALL) - B‑cell non‑Hodgkin lymphoma - Chronic lymphocytic leukemia - Myelofibrosis and myeloproliferative neoplasms - Hodgkin lymphoma - Haematologic malignancies including B‑cell lymphoid and multiple myeloma *​“The Oncology Center of Excellence reflects our commitment to rigorous, [Early Phase](https://www.avancecro.com/cro/phase-i-early-phase/) oncology development. By aligning specialized scientific, regulatory, and operational teams, we help biotech sponsors generate high-quality data earlier, inform decisive go/no-go choices, and prepare for efficient global expansion.” Gabriel Kremmidiotis, Chief Scientific Officer, Avance Clinical* *“With Avance Clinical, we offer biotech sponsors a more integrated and efficient pathway to advance important oncology therapies for patients.” George E. Peoples, M.D., FACS, Founder and Executive Chairman, LumaBridge* ## **Partner With the [Early Phase](https://www.avancecro.com/cro/phase-i-early-phase/) Oncology Specialists** Avance Clinical integrates science, sites, and strategy to help you reach critical oncology milestones with greater clarity and speed. From first-in-human design to multi-region expansion, our teams work as an extension of your program to anticipate risk and keep your trials moving. [Contact us today](https://www.avancecro.com/contact-us/)[Request A Proposal](https://www.avancecro.com/request-a-proposal/) ### Meet our **expert team** [![Gabriel Kremmidiotis](https://www.avancecro.com/wp-content/uploads/2024/05/Gabriel-K-2-aspect-ratio-800-920.jpg)](https://www.avancecro.com/meet-the-team/gabriel-kremmidiotis/) ### [Gabriel Kremmidiotis](https://www.avancecro.com/meet-the-team/gabriel-kremmidiotis/) Chief Scientific Officer [![Gabriel Kremmidiotis's LinkedIn Profile](https://www.avancecro.com/wp-content/themes/tpt/img/svg/icon-linkedin.svg)](https://linkedin.com/in/gabriel-kremmidiotis-a2b4759) [Read more](https://www.avancecro.com/meet-the-team/gabriel-kremmidiotis/) [![George Peoples](https://www.avancecro.com/wp-content/uploads/2026/02/George-Peoples-aspect-ratio-800-920.png)](https://www.avancecro.com/meet-the-team/george-peoples/) ### [George Peoples](https://www.avancecro.com/meet-the-team/george-peoples/) Executive Medical Director, Oncology Center of Excellence [![George Peoples's LinkedIn Profile](https://www.avancecro.com/wp-content/themes/tpt/img/svg/icon-linkedin.svg)](https://www.linkedin.com/in/george-peoples-md-facs-169638185/) [Read more](https://www.avancecro.com/meet-the-team/george-peoples/) [![Lee Walke](https://www.avancecro.com/wp-content/uploads/2026/02/Lee-Walke-editted-aspect-ratio-800-920.png)](https://www.avancecro.com/meet-the-team/lee-walke/) ### [Lee Walke](https://www.avancecro.com/meet-the-team/lee-walke/) Executive Director of Biometrics [![Lee Walke's LinkedIn Profile](https://www.avancecro.com/wp-content/themes/tpt/img/svg/icon-linkedin.svg)](https://www.linkedin.com/in/leewalke/) [Read more](https://www.avancecro.com/meet-the-team/lee-walke/) [![Dalal Murgai](https://www.avancecro.com/wp-content/uploads/2026/02/Dalal-Murgai-1-aspect-ratio-800-920.png)](https://www.avancecro.com/meet-the-team/dalal-murgai/) ### [Dalal Murgai](https://www.avancecro.com/meet-the-team/dalal-murgai/) Senior Vice President, Global Regulatory Affairs [![Dalal Murgai's LinkedIn Profile](https://www.avancecro.com/wp-content/themes/tpt/img/svg/icon-linkedin.svg)](https://www.linkedin.com/in/dalal-murgai-70769b/) [Read more](https://www.avancecro.com/meet-the-team/dalal-murgai/) ![Tina Scheid](https://www.avancecro.com/wp-content/uploads/2026/02/Tina-Schied-aspect-ratio-800-920.png) ### Tina Scheid Senior Site Specialist [![Tina Scheid's LinkedIn Profile](https://www.avancecro.com/wp-content/themes/tpt/img/svg/icon-linkedin.svg)](https://www.linkedin.com/in/tina-schied-471493245/) [![Mandip Gill](https://www.avancecro.com/wp-content/uploads/2026/02/Mandip-Gill-aspect-ratio-800-920.png)](https://www.avancecro.com/meet-the-team/mandip-gill/) ### [Mandip Gill](https://www.avancecro.com/meet-the-team/mandip-gill/) Site Specialist [![Mandip Gill's LinkedIn Profile](https://www.avancecro.com/wp-content/themes/tpt/img/svg/icon-linkedin.svg)](https://www.linkedin.com/in/mandip-kaur-gill-phd-509b421a4/) [Read more](https://www.avancecro.com/meet-the-team/mandip-gill/) ## **Book a meeting**